Sym004 Versus TAS-102 in Patients With mCRC
NCT03717038
·
clinicaltrials.gov ↗
PHASE3
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Stopped
Study was withdrawn due to administrative reasons
Conditions
Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Carcinoma
Interventions
DRUG:
Sym004
DRUG:
TAS-102
Sponsor
Symphogen A/S